[ET Net News Agency, 11 October 2021] Brii Biosciences Limited (02137) announced the
filing of an emergency use authorization (the EUA) application for the company's
investigational SARS-CoV-2 (virus that causes COVID-19) combination therapy,
BRII-196/BRII-198, with the U.S. Food and Drug Administration (the FDA).
Data to support the EUA filing will be submitted by the company to the FDA on a rolling
basis. (RC)